
    
      This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and
      Stage IV melanoma who have recently been treated with Denileukin Diftitox. Approximately 42
      patients with radiographically measurable melanoma who have received at least one cycle of
      Denileukin Diftitox will be enrolled and treated in the study.
    
  